The raltitrexed-vinorelbine combination: A phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 459-464

  Ferrero, Jean Marc ^a   Chamorey, Emmanuel ^a   Magné, Nicolas ^a   Leccia, Frédéric ^a   Largillier, Rémy ^a   Namer, Moïse ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Advanced breast cancer; Pharmacokinetic pharmacodynamic study; Phase I clinical trial; Raltitrexed; Vinorelbine

Indexed keywords

NAVELBINE; RALTITREXED;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CARCINOMA; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; SAFETY; SALVAGE THERAPY; THIOPHENES; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036449365     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0519-2     Document Type: Article

References (21)

1. Berruti A, Sperone P, Bottini A, et al (2000) Phase II study of vinorelbine with protracted fluorouracil infusion as a second-or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18:3370
2. Burstein HJ, Bunnel CA, Winer EP (2001) New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol 28:344
3. Cascinu S, Silva RR, Labianca R, Barni S, Mattioli R, Martignoni G, Frontini L, Gasparini G, Catalano V, Baldelli AM, Giuliodori L, Agostinelli R, Catalano G (1999) A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 10:985
4. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson LR (1996) Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495
5. Danova M, Porta C, Ferrari S, Riccardi A (2001) Strategies of medical treatment for metastatic breast cancer. Int J Oncol 19:733
6. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215
7. Dieras V, Extra JM, Bellisant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M (1996) Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14:3097
8. European Society of Medical Oncology (2001) ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 12:1047
9. Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F (2000) Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6:2690
10. Gregory RK, Smith IE (2000) Vinorelbine - A clinical review. Br J Cancer 82:1907
11. Gunasekara NS, Faulds D (1998) Raltitrexed. A review of its pharmacological properties and clinical e3cacy in the management of advanced colorectal cancer. Drugs 55:423
12. Lombardi D, Magri MD, Crivellari D, Spazzapan S, Paolello C, De Cicco M, Di Lauro V, Scuderi C, Veronesi A (2000) Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol 11:1041
13. Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 36:37
14. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627
15. Pienkowski T, Jagiello-Gruszfeld A (2001) Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 21:111
16. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S (1996) Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59:32
17. Smith I, Jones A, Spielman M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J, Seymour L (1996) A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74:479
18. Sorio R, Robieux I, Galligioni E, Freschi A, Colussi AM, Crivellari D, Saracchini S, Monfardini S (1997) Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33:301
19. Vogel CL, Nabholtz JM (1999) Monotherapy of metastatic breast cancer: A review of newer agents. Oncologist 4:17
20. Zambelli A, Robustelli della Cuna FS, Ponchio L, Ucci G, Da Prada GA, Robustelli della Cuna G (2000) Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 61:241
21. Zambetti M, Mariani G, Demicheli R, Verderio P, Potepan P, Garbagnati F (2000) Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. Breast Cancer Res Treat 62:135